NCT03385096

Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT

Melphalan vs Busulfan+ Cyclophosphamide+ Etoposide Conditioning Regimen for Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 122 (estimated)
• Sponsor: Nanfang Hospital, Southern Medical University · Academic / Other
• Sex: All
• Age: 14 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of Melphalan and BUCY+VP-16 myeloablative conditioning regimens in multiple myeloma undergoing autologous hematopoietic stem cell transplantation.

Conditions

• Autologous Hematopoietic Stem Cell Transplantation
• Conditioning
• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Busulfan (BU)	Busulfan was administered at 3.2 mg/kg/day on days -8 to -6. -7 to -4.
DRUG	Cyclophosphamide (CY)	Cyclophosphamide was administered at 60 mg/kg/day on days -5 to -4. on days -3 to -2.
DRUG	Etoposide (VP-16)	Etoposide was administered at 10 mg/kg/day on days -3 to -2. -3 to -2.
DRUG	Melphalan	Melphalan was administered at 200mg/m2 on day -2.

Timeline

• Start date: 2018-01-02
• Primary completion: 2020-12-01
• Completion: 2021-12-01
• First posted: 2017-12-28
• Last updated: 2020-02-25

Locations

1 site across 1 country: China